欧洲疾控中心-关于指定未来欧洲公共卫生参考实验室的快速ECDC建议（英）-2025_6页_812kb

ECDC proposes the designation of European Reference Laboratories (EURLs) for public health in 2025 and beyond. The selection process is managed by DG SANTE, with prioritization based on public health needs, stakeholder input, and budget considerations.

Proposed EURL(s) for implementation in 2025/2026:

• Respiratory viruses, including influenza, SARS-CoV-2, and respiratory syncytial virus (RSV).
• This includes merging existing networks (ERLI-Net and ECOVID-LabNet) and nominating Operational Contact Points for RSV to ensure coordination.
• Rationale: High priority due to pandemic potential, existing surveillance burden, and the need for capacity-building in laboratory support.

Proposed EURLs for implementation in coming years:

• Healthcare-associated infections (e.g., Clostridioides difficile).
• (Antimicrobial-resistant) Gonorrhoea.
• Tuberculosis.
• Invasive Bacterial Diseases (e.g., meningococcal disease, pneumococcal disease).

Additional diseases/health issues under consideration:

• Arthropod vectors, considering climate change impacts and surveillance needs.
• Prion diseases, supporting rare but high-impact events.
• Fungal pathogens, addressing increasing drug resistance.
• Mycoplasma infections, noting recent case increases.
• Wastewater surveillance, aligning with future monitoring needs.

Proposed changes in processes:

• Application forms updated to better address crisis preparedness, especially for relevant EURLs.
• Selection criteria revised to eliminate confusion about 'laboratory networks'.
• Funding process adjusted to allow for multiple EU4Health grants during the designation period and inclusion of mandatory deliverables in applications.

Methods for prioritization:

• Internal ECDC discussions with subject matter experts.
• Stakeholder feedback from disease networks, advisory bodies, and national authorities.
• Contractual status and budget allocations under EU4Health.

Conclusion and recommendations:

• DG SANTE should designate an EURL for respiratory viruses.
• Revise the EURL implementation process as proposed.
• Conduct a 2025 stakeholder consultation on potential future EURLs for additional diseases.